Tiplaxtinin

Tiplaxtinin is an inhibitor of plasminogen activator inhibitor 1 (PAI-1; IC₅₀ = 2.7 μM for the human enzyme). It inhibits differentiation of human adipocytes when used at a concentration of 5 μM. Tiplaxtinin (5 and 20 mg/kg) reduces tumor growth and microvessel density in a T24 bladder cancer mouse xenograft model. It prevents carotid artery occlusion, increases the time to occlusive thrombosis, and decreases the thrombus size in a rat model of ferric chloride-induced arterial thrombosis when administered at a dose of 1 mg/kg.

Tiplaxtinin inhibits smooth muscle cells (SMC) migration and intimal hyperplasia. A novel therapeutic agent to improve diabetic wound.

ChEBI: Tiplasinin is a member of indole-3-acetic acids. It is a potent and selective PAI-1 inhibitor. Tiplaxtinin demonstrated efficacy in vivo in multiple models of acute arterial thrombosis and has been shown to reduce physiologic PAI-1 activity.

Tiplaxtinin has high oral bioavailability. It is metabolically stable and shows large safety multiples in animal toxicology studies. Tiplaxtinin can be easily synthesized in bulk quantities. This drug also reduces diet-induced obesity in mice.

Store at +4°C